Diabetes

Weight Loss Maintenance Important for Cardiometabolic Risk Control in T2D

Publish Date October 16, 2019

A larger percentage of weight loss regained after an intensive lifestyle intervention was positively associated with certain cardiometabolic risk factors in type 2 diabetes.

Poor Glycemic Control May Up Risk for Stroke, Death in T2DM

Publish Date October 11, 2019

Risk for stroke, death increased with each 10 mmol/mol increase in HbA1c level.

With Comorbidities, Less Than 6 Hours of Sleep Ups Risk for Early Death

Publish Date October 14, 2019

Risk for dying from heart attack, stroke higher among those with high blood pressure, diabetes and short sleep.

Pioglitazone May Reduce Overall Mortality Risk in Patients With Type 2 Diabetes

Publish Date October 9, 2019

Findings showed that the combination of insulin and pioglitazone lowered all-cause mortality risk, and this combination therapy exerted beneficial effects on noncardiovascular deaths.

For Seniors With T2DM, Insulin Use Up With Poor Health

Publish Date September 27, 2019

Individuals with poor and intermediate versus good health more likely to continue insulin use

Cardiorenal Disease Is the Most Common CVD Manifestation in Patients With T2D

Publish Date September 19, 2019

Cardiorenal disease is commonly the first cardiovascular disease manifestation in patients with type 2 diabetes.

Dapagliflozin Lowers Risk for Worsening Heart Failure

Publish Date September 23, 2019

Findings seen among patients with heart failure, reduced ejection fraction, irrespective of diabetes

SGLT2 Inhibitors Linked to Lower Risk for Heart Failure

Publish Date September 20, 2019

Risk lower for heart failure, but not major CV events, compared with new users of DPP4 inhibitors.

Linagliptin Noninferior for CV Risk in Early Type 2 Diabetes

Publish Date September 19, 2019

Linagliptin compared with glimepiride for risk for major cardiovascular events in T2DM with elevated CV risk

First Oral GLP-1 Receptor Agonist Approved for Type 2 Diabetes

Publish Date September 23, 2019

Rybelsus is the first glucagon-like peptide (GLP-1) available in a tablet formulation that is approved for once daily use